These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25170863)

  • 1. Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
    Enders P; Muether PS; Hermann M; Ristau T; Fauser S
    Retina; 2015 Mar; 35(3):454-8. PubMed ID: 25170863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
    Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
    Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
    Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
    J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
    Carneiro AM; Costa R; Falcão MS; Barthelmes D; Mendonça LS; Fonseca SL; Gonçalves R; Gonçalves C; Falcão-Reis FM; Soares R
    Acta Ophthalmol; 2012 Feb; 90(1):e25-30. PubMed ID: 21958440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
    Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G; Giansanti F; Finocchio L; Biagini I; Bacherini D; Virgili G; Menchini U
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Angermann R; Huber AL; Nowosielski Y; Salcher S; Gasser T; Seifarth C; Kralinger MT; Zehetner C
    Retina; 2022 Mar; 42(3):503-510. PubMed ID: 34731094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years.
    Abedi F; Wickremasinghe S; Islam AF; Inglis KM; Guymer RH
    Retina; 2014 Aug; 34(8):1531-8. PubMed ID: 24637667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
    Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H
    Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
    Bloch SB; Lund-Andersen H; Sander B; Larsen M
    Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.
    Mendrinos E; Mangioris G; Papadopoulou DN; Donati G; Pournaras CJ
    Acta Ophthalmol; 2013 May; 91(3):e184-90. PubMed ID: 23590391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.